PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
88.64%
Cash & equivalents changing by 88.64% while Medical - Pharmaceuticals maintains stable levels. Benjamin Graham would examine if this divergence is justified.
No Data
No Data available this quarter, please select a different quarter.
88.64%
Below half the Medical - Pharmaceuticals median of -0.19% yoy growth. Jim Chanos might see inadequate liquidity buildup relative to peers. Verify free cash flow trends.
32.94%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
10.47%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-12.91%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
27.86%
Current assets growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a potential liquidity edge if well allocated.
5.24%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-0.73%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-0.73%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
410.78%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
153.63%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
-286.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
5.25%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
250.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
11.68%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
19.34%
Payables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-36.24%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
80.99%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
598.62%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a robust subscription base vs. peers.
-36.08%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
17.36%
Above 1.5x Medical - Pharmaceuticals median of 1.42%. Jim Chanos suspects potential working capital strain.
394.72%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-46.62%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
82.90%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
21.05%
Above 1.5x Medical - Pharmaceuticals median of 0.61%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
3.85%
Below half Medical - Pharmaceuticals median of -0.24%. Jim Chanos suspects poor profitability or large dividend drains.
233.33%
Above 1.5x Medical - Pharmaceuticals median 5.65%. Jim Chanos suspects a red flag if these gains are highly volatile.
No Data
No Data available this quarter, please select a different quarter.
3.71%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees stronger equity growth vs. peers.
11.68%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees more aggressive expansions than peers.
-99.91%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential underinvestment or forced liquidation vs. peers.
187.81%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-53.84%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.